Wen Qiang, Wang Weiqi, Zhang Ke, Pan Chunguo, Liu Zhihua, Wang Lei
Department of Radiation Oncology, Jiangxi Cancer Hospital and Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
Department of Oncology, Nanchang University, Jiangxi Cancer Hospital and Institute, Nanchang, Jiangxi, China.
Front Immunol. 2025 Aug 22;16:1613974. doi: 10.3389/fimmu.2025.1613974. eCollection 2025.
We present a case of a 68-year-old male with advanced non-small cell lung cancer (NSCLC), PD-L1 negative and driver gene negative, who exhibited a significant abscopal effect following radiotherapy combined with systemic immunotherapy (sintilizumab) and chemotherapy. The patient achieved complete remission (CR) of intracranial metastases without cranial irradiation, suggesting a systemic immune response triggered by the combination of radiotherapy and immunotherapy. This case highlights the potential of radiotherapy combined with immuno-chemotherapy to induce abscopal effects, even in PD-L1 negative patients, and underscores the importance of further investigation into this therapeutic strategy. This case challenges traditional paradigms in NSCLC management and aligns with emerging theragnostic approaches that integrate localized treatment with systemic immune modulation.
我们报告一例68岁男性晚期非小细胞肺癌（NSCLC）患者，其程序性死亡配体1（PD-L1）阴性且驱动基因阴性，在放疗联合全身免疫治疗（信迪利单抗）及化疗后出现显著的远隔效应。该患者未进行颅脑照射即实现颅内转移灶完全缓解（CR），提示放疗与免疫治疗联合触发了全身免疫反应。本病例突出了放疗联合免疫化疗诱导远隔效应的潜力，即便在PD-L1阴性患者中亦是如此，并强调了进一步研究这一治疗策略的重要性。该病例挑战了NSCLC治疗的传统模式，与将局部治疗与全身免疫调节相结合的新兴诊疗方法相契合。
